Clinical trials: Secondary Progressive Multiple Sclerosis
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS
- Trial name
- NCT06384976
- Testing
- KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Kyverna Therapeutics
Primary Progressive Multiple Sclerosis, Multiple Sclerosis
A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).
- Conditions
- Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06900192
- Testing
- Orca-Q, myeloablative regimen
- Volunteers
- 10 people
- Sponsor
- Stanford University
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of…
- Trial name
- EMBOLD (NCT03283826)
- Testing
- ATA188
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- Atara Biotherapeutics
Secondary Progressive Multiple Sclerosis
Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis
Secondary progressive multiple sclerosis (SPMS) is a subtype of multiple sclerosis (MS) for which there are no existing therapies that alter the disease course.
- Trial name
- NCT01647321
- Testing
- Active cycling, Passive cycling
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Johns Hopkins University
Secondary Progressive Multiple Sclerosis
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with…
- Trial name
- NCT07299019
- Testing
- Orelabrutinib
- Where
- 69 sites in United States, Australia and 14 more
- Volunteers
- 990 people
- Sponsor
- Zenas BioPharma (USA), LLC
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).
The aim of this study is to identify whether it is possible to safely discontinue treatment in relapsing-onset MS patients who have shown no evidence of active inflammation in the years prior to inclusion clinically and/or…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- DOT-MS (NCT04260711)
- Testing
- DMT
- Where
- Netherlands
- Volunteers
- 130 people
- Sponsor
- Amsterdam UMC, location VUmc
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06390930
- Testing
- Acute Intermittent Hypoxia
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Shirley Ryan AbilityLab
Secondary-progressive Multiple Sclerosis
Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients
This will be a phase I, open, multicenter, international study performed by 3 participating centres across two countries (Italy and Switzerland).
- Trial name
- NSC-SPMS (NCT03282760)
- Testing
- Human Neural Stem Cells
- Where
- 3 sites in Italy, Switzerland
- Volunteers
- 24 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
This study is a national, prospective, multicenter, non-interventional (observational) study with the aim to describe the impact of Siponimod treatment in a real-world SPMS population in Switzerland who are treated with Siponimod…
- Trial name
- SWISSMASIA (NCT04895202)
- Testing
- Siponimod
- Where
- 6 sites in Switzerland
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Multiple Sclerosis
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration…
- Trial name
- FREVIVA (NCT06141486)
- Testing
- Frexalimab, MRI contrast-enhancing agents
- Where
- 311 sites in United States, Argentina and 25 more
- Volunteers
- 943 people
- Sponsor
- Sanofi
Multiple Sclerosis, Chronic Progressive
Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
Preliminary not-controlled clinical studies of the efficacy of monthly intravenous cyclophosphamide administration in secondary progressive multiple sclerosis reported encouraging results, but no randomized controlled trial has…
- Trial name
- PROMESS (NCT00241254)
- Testing
- Cyclophosphamide (drug), Methylprednisolone (drug)
- Where
- 26 sites in France
- Volunteers
- 138 people
- Sponsor
- University Hospital, Bordeaux
Secondary Progressive Multiple Sclerosis
A Study for Patients With Secondary Progressive Multiple Sclerosis
The purpose of this study is to determine whether MBP8298 is effective and safe in the treatment secondary progressive multiple sclerosis. Dirucotide is generic name for MBP8298.
- Trial name
- MAESTRO-01 (NCT00869726)
- Testing
- dirucotide
- Where
- 10 sites in Canada, Denmark and 8 more
- Volunteers
- 596 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
The purpose of the study is to evaluate if the higher dose can give greater efficacy without negative impact on the adverse event profile for patients with early secondary progressive Multiple Sclerosis (SPMS).
- Trial name
- NCT00313976
- Testing
- Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
- Where
- 7 sites in Denmark, Sweden
- Sponsor
- Bayer
Multiple Sclerosis, Progressive Multiple Sclerosis
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
This is a three-week crossover study that will compare how the body absorbs and tolerates two different forms of lipoic acid: R form and racemic form.
- Conditions
- Multiple Sclerosis, Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Trial name
- NCT03493841
- Testing
- Alpha Lipoic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rebecca Spain
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis
PHOMS Study is a randomized, controlled, open-label, prospective, and multicentric clinical trial involving outpatients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Relapsing-Remitting Multiple Sclerosis…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- PHOMS (NCT05168384)
- Testing
- Extracorporeal Photopheresis, MS standard of care
- Where
- United Arab Emirates
- Volunteers
- 15 people
- Sponsor
- Abu Dhabi Stem Cells Center
Multiple Sclerosis, Secondary Progressive
Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects with Secondary Progressive Multiple Sclerosis (SPMS)
- Trial name
- MAESTRO-03 (NCT00468611)
- Testing
- MBP8298
- Volunteers
- 510 people
- Sponsor
- BioMS Technology Corp.
Secondary Progressive Multiple Sclerosis
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
The primary goal of this study is to evaluate the effects of BAF312 (siponimod) on select immune and neuronal (nerve) cells by examining laboratory specimens (blood and/or spinal fluid) at multiple time points, prior to, and…
- Trial name
- NCT02330965
- Testing
- Blood Draw, CSF collection by lumbar puncture (Optional)
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
The study goal is to establish the equivalence of pharmacokinetic (PK) properties, as well as the comparability of safety, immunogenicity (IG) and pharmacodynamics (PD) of the drug product RPH-035 (R-Pharm JSC, Russia) in…
- Trial name
- NCT07597668
- Testing
- RPH-035, Ocrevus®
- Where
- 23 sites in Russia
- Volunteers
- 180 people
- Sponsor
- R-Pharm
Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
The purpose of the study is to evaluate the efficacy and safety of subcutaneously administered cladribine versus placebo to stop inflammation and treat disease progression of non-active secondary progressive multiple sclerosis.
- Trial name
- CLASP-MS (NCT05961644)
- Testing
- Cladribine Subcutaneous Injection, 0.9% Chloride Injection Sodium
- Where
- Poland
- Volunteers
- 188 people
- Sponsor
- Institute of Psychiatry and Neurology, Warsaw